Back

Aficamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy: SEQUOIA-HCM an international multicenter phase 3 trial

13 May 2024 (14:09 - 14:17)
Organised by: Logo
Congress Presentation Part of: Late breaking clinical trials: LVAD, HFpEF and hypertrophic cardiomyopathy Hypertrophic Cardiomyopathy HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Martin Maron

Lahey Hospital & Medical Centre, Burlington (United States of America)

9 More presentations in this session

Presentation thumbnail
Outcomes with aspirin avoidance after implantation of a Fully Magnetically Levitated LVAD in patients with coronary, cerebral or peripheral vascular disease: the ARIES HM3 randomized clinical trial
Professor F. Gustafsson (Pleasanton, US)
Slides Video
Presentation thumbnail
Discussant review - ARIES
Doctor O. Dar (London, GB)
Slides Video
Presentation thumbnail
Semaglutide therapy and diuretic use in obesity-related HFpEF: insights from the STEP-HFpEF programme
Professor S. Verma (Toronto, CA)
Slides Video
Presentation thumbnail
Discussant review - STEP-HFpEF Programme
Assistant Professor D. Farmakis (Athens, GR)
Slides Video
Presentation thumbnail
Discussant review - Quantitative Understanding of Obstruction Impact of Aficamten in HCM
Professor P. Elliott (London, GB)
Slides Video

Access the full session

Session thumbnail
Late breaking clinical trials: LVAD, HFpEF and hypertrophic cardiomyopathy
Video

The Event

Event poster

Heart Failure 2024

13 May 2024 14:09 CET
You may be interested in
thumbnail
Congress Presentation
Semaglutide therapy and diuretic use in obesity-related HFpEF: insights from the STEP-HFpEF programme
thumbnail
Congress Presentation
Discussant review - Quantitative Understanding of Obstruction Impact of Aficamten in HCM
thumbnail
Congress Presentation
Discussant review - STEP-HFpEF Programme

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources